Lupin pharmaceuticals has entered into an agreement with Nichi-Iko for the distribution, promotion, and sale of its proposed biosimilar etanercept, YLB113, in Japan.
Lupin pharmaceuticals announced this week that it has entered into an agreement with Nichi-Iko for the distribution, promotion, and sale of its proposed biosimilar etanercept, YLB113, in Japan.
The proposed biosimilar, which is awaiting Japanese regulatory approval, was developed by YL Biologics in a joint venture between a subsidiary of Lupin, Lupin Atlantis Holdings SA, and Yoshindo. In March, YLB113 was submitted for regulatory approval to the Pharmaceuticals and Medicals Device Agency (PMDA) in Japan following conclusion of a phase 3 study.
The study was a 52-week, multinational, randomized, double-blind, controlled trial that included more than 500 patient with rheumatoid arthritis (RA) in 11 countries. The trial sought to determine the efficacy and safety of YLB113 compared directly with the reference etanercept product, Enbrel.
Researchers found that the safety and immunogenicity of YLB113 were similar to those of the reference product. In addition, the study achieved its primary endpoint of equivalent improvement in RA, as measured by the American College of Rheumatology’s criteria for 20% improvement, or ACR20.
“The successful commercialization of our first biosimilar will help our foray into the fast-growing biologics space and also provide patients in Japan access to a high quality, affordable alternative,” said Nilesh Gupta, managing director of Lupin Limited in a statement.
If it receives regulatory approval, the product will be launched in Japan by Nichi-Iko.
In addition to filing the potential biosimilar for approval in Japan, Lupin has also submitted a marketing authorization application for YLB113 to the European Medicine’s Agency for the treatment of RA, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.